Arthroscopic SurgeryNCT07468045
Functional Outcomes After Hyaluronic Acid Injections Following Arthroscopy
A study testing CG Synovia (Hyaluronic Acid 0.5%) in people with Arthroscopic Surgery, run by Daewoong Group Indonesia at 2 sites in Indonesia.
Trial summary
The goal of this study is to investigate the effect of hyaluronic acid injection on functional recovery and pain control in patients following knee or shoulder arthroscopy. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Arthroscopic Surgery
- What is being tested?
- CG Synovia (Hyaluronic Acid 0.5%)
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 9 participants
- Where
- 2 sitesIndonesia
- Study dates
- 9 Oct 2024to 7 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Male and female adults aged 18 to 60 years at the date of the written informed consent form.
- Patient with surgery scheduled for arthroscopic procedure on knee or shoulder.
- Those who could understand the provided information and were able to fill out the questionnaire.
- Those who voluntarily decided to participate in the study and wrote the informed consent form.
Who cannot join
- In the following cases that may affect test results
- Patients with history and suspected of rheumatoid arthritis (RA).
- Patients with osteoarthritis in the joint related to specific joint movement.
- Those with a history of surgery in the related area of the join that affect join movement.
- Patients with infection at the surgical site.
- Patients with chronic diseases that may affect surgery, such as uncontrolled diabetes or uncontrolled high blood pressure.
Show all 17Show fewer
- Patients with complex regional pain syndrome.
- If adverse reactions are expected during surgery in the following cases:
- People taking blood coagulants or patients with diseases that require blood coagulants.
- When there are restrictions on the use of anticoagulants or antithrombotic agents.
- Those with confirmed severe liver dysfunction or decreased renal function.
- Patients with other serious systemic diseases such as severe anemia.
- Known HIV positive person receiving medication.
- Patients are allergic to substances used in medical devices for the study (Hyaluronic Acid).
- Pregnant, lactating, or women of childbearing potential who are unwilling to use contraception during the study.
- Use of drugs or medical devices due to participation in other study
- Other people deemed inappropriate to participate in the test by the investigator (including high probability of noncompliance).
Trial locations and contacts
2 sites in 1 country.
Indonesia2 sites
Siloam Hospitals Mampang
Jakarta, 12760
MRCCC Siloam Hospitals Semanggi
Jakarta, 12930
About this study
Official title: Evaluation of Functional Outcomes in Patients Receiving Hyaluronic Acid Injections Following Arthroscopic Procedure
The goal of this study is to investigate the effect of hyaluronic acid injection on functional recovery and pain control in patients following knee or shoulder arthroscopy.
Read the detailed description
The study consists of three main periods: screening, treatment, and follow-up. During the screening period, subjects will provide written informed consent and undergo screening assessments. Only those who meet all inclusion criteria and none of the exclusion criteria will be enrolled in the study.
During the treatment period, before completing the arthroscopy procedure, 10 mL of Hyaluronic Acid 0.5% (CG Synovia) will be injected into the joint cavity through the existing arthroscopy portal using a suitable needle attached to a Luer lock. The joint will then be moved through its full range of motion to ensure proper distribution of the product within the joint.
During the follow-up period, subjects will attend visits up to 24 weeks after treatment, specifically at 4 weeks (Visit 3), 12 weeks (Visit 4), and 24 weeks (Visit 5) for evaluation.
- Conditions
- Arthroscopic Surgery
- Being tested
- CG Synovia (Hyaluronic Acid 0.5%)
- Keywords
- Hyaluronic Acid, Knee Arthroscopy, Shoulder Arthroscopy, Arthroscopy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CG Synovia (Hyaluronic Acid 0.5%)Device
After arthroscopic procedure, attach a suitable needle to the Luer Lock and inject 10ml of CG Synovia into the joint cavity through a portal already placed in the joint for arthroscopy. Move the joint through full range of motion to allow CG Synovia to distribute throughout the joint, synovium, and joint surfaces.
| Study group | Role | What they receive |
|---|---|---|
| Hyaluronic Acid 0,5% | Experimental | Hyaluronic Acid 0,5%. 10ml pre-filled syringe for single use. Syringe equipped with Luer Lock which can be a safe needle attachment. Receives: Device: CG Synovia (Hyaluronic Acid 0.5%) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety Evaluation
Safety evaluation will be measured by monitoring the Adverse Events (AE)
Measured: 4, 12 and 24 weeks
Change from baseline to 4 weeks in Haemoglobin concentration
Haemoglobin concentration count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : g/dL
Measured: 4 weeks
Change from baseline to 4 weeks in Haematocrit
Haematocrit count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : %
Measured: 4 weeks
Change from baseline to 4 weeks in White Blood Cell (WBC) count
White Blood Cell (WBC) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit 10³/µL
Measured: 4 weeks
Change from baseline to 4 weeks in Platelet count
Platelet count count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : 10³/µL
Measured: 4 weeks
Change from baseline to 4 weeks in Basophils (differential)
Basophils (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : %
Measured: 4 weeks
Change from baseline to 4 weeks in Eosinophils (differential)
Eosinophils (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : %
Measured: 4 weeks
Change from baseline to 4 weeks in Neutrophils (differential)
Neutrophils (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : %
Measured: 4 weeks
Change from baseline to 4 weeks in Lymphocytes (differential)
Lymphocytes (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : %
Measured: 4 weeks
Change from baseline to 4 weeks in Monocytes (differential)
Monocytes (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : %
Measured: 4 weeks
Change from baseline to 4 weeks in Random Blood Glucose
Random Blood Glucose count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : mg/dL
Measured: 4 weeks
Change from baseline to 4 weeks in Urea
Urea count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : mg/dL
Measured: 4 weeks
Change from baseline to 4 weeks in Creatinine
Creatinine count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : mg/dL
Measured: 4 weeks
Change from baseline to 4 weeks in Aspartate aminotransferase (AST)
Aspartate aminotransferase (AST) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : U/L
Measured: 4 weeks
Change from baseline to 4 weeks in Alanine aminotransferase (ALT)
Alanine aminotransferase (ALT) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : U/L
Measured: 4 weeks
Change from baseline to 4 weeks in Prothrombin time (PT)
Prothrombin Time (PT) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : Seconds
Measured: 4 weeks
Change from baseline to 4 weeks in Activated partial thromboplastin time (aPTT)
Activated Partial Thromboplastin Time (aPTT) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : Seconds
Measured: 4 weeks
Change from baseline to 4 weeks in International normalised ratio (INR)
International Normalised Ratio (INR) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks.
Unit : Ratio
Measured: 4 weeks
Change from baseline to Weeks 4, 12, and 24 in active knee flexion range of motion
Active knee flexion ROM (degrees) will be measured in the operated knee using a standard goniometer during clinical examination. Higher values indicate greater joint mobility.
Unit : degrees
Measured: Baseline and Weeks 4, 12, 24
Change from baseline to Weeks 4, 12, and 24 in active shoulder abduction range of motion
description : Active shoulder abduction ROM (degrees) will be measured in the operated shoulder using a standard goniometer during clinical examination. Higher values indicate greater joint mobility.
Unit : degrees
Measured: Baseline and Weeks 4, 12, 24
Change from baseline to Weeks 4, 12, and 24 in active shoulder adduction range of motion
Active shoulder adduction ROM (degrees) will be measured in the operated shoulder using a standard goniometer during clinical examination. Higher values indicate greater joint mobility.
Unit : degrees
Measured: Baseline and Weeks 4, 12, 24
Change from baseline to Weeks 4, 12, and 24 in active shoulder flexion range of motion
Active shoulder flexion ROM (degrees) will be measured in the operated shoulder using a standard goniometer during clinical examination. Higher values indicate greater joint mobility.
Unit : degrees
Measured: Baseline and Weeks 4, 12, 24
Change from baseline to Weeks 4, 12, and 24 in active shoulder extension range of motion
Active shoulder extension ROM (degrees) will be measured in the operated shoulder using a standard goniometer during clinical examination. Higher values indicate greater joint mobility.
Unit : degrees
Measured: Baseline and Weeks 4, 12, 24
Exploratory Outcome
Change from baseline in functional score related to shoulder joints using Shoulder and Pain Disability Index (SPADI) questionnaire which is a self-administered questionnaire that assesses shoulder pain and functional disability.
It consists of two domains: a pain domain with five questions assessing the severity of pain (0 = no pain to 10 = worst pain imaginable), and a disability domain with eight questions evaluating the degree of difficulty in performing activities of daily living requiring upper-extremity use (0 = no difficulty to 10 = so difficult it requires help).
The final score is calculated by summing the 5 pain items and 8 disability items, converting each subscale to a percentage of its maximum possible score, and averaging the two subscales to obtain a total score ranging from 0 to 100. higher scores indicating greater pain and disability (worse outcome).
Measured: 4, 12 and 24 weeks
Exploratory Outcome
Change from baseline in functional score related to knee joints using The Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire which is a patient-reported questionnaire used to assess pain, stiffness, and physical function in individuals with knee osteoarthritis.
The questionnaire consists of 24 items divided into three subscales: pain (5 items), stiffness (2 items), and physical function (17 items). Each item is scored on a scale from 0 to 4, and the total score ranges from 0 to 96, with higher scores indicating worse pain, stiffness, and functional limitation.
Measured: 4, 12 and 24 weeks
Exploratory Outcome
Pain score will be assessed based on the change from baseline in the Numeric Rating Scale (NRS) from 1-10 where 0 indicates no pain and 10 indicates the worst pain imaginable.
Measured: 4, 12 and 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2026
- Study start9 Oct 2024
- Primary completion7 Jul 2025
- Study completion7 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Arthroscopic SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 9 participants (actual)
Sponsor and investigators
- Lead sponsor
- Daewoong Group Indonesia
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- CGBio Neoregen Indonesia
- Responsible party
- Sponsor
- Investigators
- Prof. Dr. dr. Andri Marulitua Lubis Sp.OT(K), Principal investigator, Siloam Hospitals Mampang
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07468045
- Sponsor's protocol ID
- CG-SYN62001
- Status last verified
- Oct 2026
- First submitted
- 25 Feb 2026
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Functional Outcomes in Patients Receiving Hyaluronic Acid Injections Following Arthroscopic Procedure
- ClinicalTrials.gov ID
- NCT07468045
- Acronym / sponsor ID
- CG-SYN62001
- Conditions
- Arthroscopic Surgery
- Keywords
- Hyaluronic Acid, Knee Arthroscopy, Shoulder Arthroscopy, Arthroscopy
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 9 participants (actual)
- Lead sponsor
- Daewoong Group IndonesiaIndustry (pharma, biotech, devices)
- Collaborators
- CGBio Neoregen Indonesia
- Study start
- 9 Oct 2024 (actual)
- Primary completion
- 7 Jul 2025 (actual)
- Study completion
- 7 Jul 2025 (actual)
- First posted
- 12 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to investigate the effect of hyaluronic acid injection on functional recovery and pain control in patients following knee or shoulder arthroscopy.
Detailed description
The study consists of three main periods: screening, treatment, and follow-up. During the screening period, subjects will provide written informed consent and undergo screening assessments. Only those who meet all inclusion criteria and none of the exclusion criteria will be enrolled in the study.
During the treatment period, before completing the arthroscopy procedure, 10 mL of Hyaluronic Acid 0.5% (CG Synovia) will be injected into the joint cavity through the existing arthroscopy portal using a suitable needle attached to a Luer lock. The joint will then be moved through its full range of motion to ensure proper distribution of the product within the joint.
During the follow-up period, subjects will attend visits up to 24 weeks after treatment, specifically at 4 weeks (Visit 3), 12 weeks (Visit 4), and 24 weeks (Visit 5) for evaluation.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Hyaluronic Acid 0,5% | Experimental | Device: CG Synovia (Hyaluronic Acid 0.5%)Hyaluronic Acid 0,5%. 10ml pre-filled syringe for single use. Syringe equipped with Luer Lock which can be a safe needle attachment. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Male and female adults aged 18 to 60 years at the date of the written informed consent form.
- Patient with surgery scheduled for arthroscopic procedure on knee or shoulder.
- Those who could understand the provided information and were able to fill out the questionnaire.
- Those who voluntarily decided to participate in the study and wrote the informed consent form.
Key exclusion criteria (17 listed)
- In the following cases that may affect test results
- Patients with chronic diseases that may affect surgery, such as uncontrolled diabetes or uncontrolled high blood pressure.
- Patients with complex regional pain syndrome.
- If adverse reactions are expected during surgery in the following cases:
- Patients are allergic to substances used in medical devices for the study (Hyaluronic Acid).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CG Synovia (Hyaluronic Acid 0.5%)After arthroscopic procedure, attach a suitable needle to the Luer Lock and inject 10ml of CG Synovia into the joint cavity through a portal already placed in the joint for arthroscopy. Move the joint through full range of motion to allow CG Synovia to distribute throughout the joint, synovium, and joint surfaces. | Device | Hyaluronic Acid 0,5% |
Primary outcome
Safety Evaluation
Time frame: 4, 12 and 24 weeks
Safety evaluation will be measured by monitoring the Adverse Events (AE)
Change from baseline to 4 weeks in Haemoglobin concentration
Time frame: 4 weeks
Haemoglobin concentration count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : g/dL
Change from baseline to 4 weeks in Haematocrit
Time frame: 4 weeks
Haematocrit count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %
Change from baseline to 4 weeks in White Blood Cell (WBC) count
Time frame: 4 weeks
White Blood Cell (WBC) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit 10³/µL
Change from baseline to 4 weeks in Platelet count
Time frame: 4 weeks
Platelet count count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : 10³/µL
Change from baseline to 4 weeks in Basophils (differential)
Time frame: 4 weeks
Basophils (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %
Change from baseline to 4 weeks in Eosinophils (differential)
Time frame: 4 weeks
Eosinophils (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %
Change from baseline to 4 weeks in Neutrophils (differential)
Time frame: 4 weeks
Neutrophils (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %
Change from baseline to 4 weeks in Lymphocytes (differential)
Time frame: 4 weeks
Lymphocytes (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %
Change from baseline to 4 weeks in Monocytes (differential)
Time frame: 4 weeks
Monocytes (differential) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : %
Change from baseline to 4 weeks in Random Blood Glucose
Time frame: 4 weeks
Random Blood Glucose count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : mg/dL
Change from baseline to 4 weeks in Urea
Time frame: 4 weeks
Urea count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : mg/dL
Change from baseline to 4 weeks in Creatinine
Time frame: 4 weeks
Creatinine count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : mg/dL
Change from baseline to 4 weeks in Aspartate aminotransferase (AST)
Time frame: 4 weeks
Aspartate aminotransferase (AST) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : U/L
Change from baseline to 4 weeks in Alanine aminotransferase (ALT)
Time frame: 4 weeks
Alanine aminotransferase (ALT) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : U/L
Change from baseline to 4 weeks in Prothrombin time (PT)
Time frame: 4 weeks
Prothrombin Time (PT) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : Seconds
Change from baseline to 4 weeks in Activated partial thromboplastin time (aPTT)
Time frame: 4 weeks
Activated Partial Thromboplastin Time (aPTT) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : Seconds
Change from baseline to 4 weeks in International normalised ratio (INR)
Time frame: 4 weeks
International Normalised Ratio (INR) count will be measured from venous blood samples analyzed by the site clinical laboratory using standard methods. Values will be summarized as change from baseline to 4 weeks. Unit : Ratio
Change from baseline to Weeks 4, 12, and 24 in active knee flexion range of motion
Time frame: Baseline and Weeks 4, 12, 24
Active knee flexion ROM (degrees) will be measured in the operated knee using a standard goniometer during clinical examination. Higher values indicate greater joint mobility. Unit : degrees
Change from baseline to Weeks 4, 12, and 24 in active shoulder abduction range of motion
Time frame: Baseline and Weeks 4, 12, 24
description : Active shoulder abduction ROM (degrees) will be measured in the operated shoulder using a standard goniometer during clinical examination. Higher values indicate greater joint mobility. Unit : degrees
Change from baseline to Weeks 4, 12, and 24 in active shoulder adduction range of motion
Time frame: Baseline and Weeks 4, 12, 24
Active shoulder adduction ROM (degrees) will be measured in the operated shoulder using a standard goniometer during clinical examination. Higher values indicate greater joint mobility. Unit : degrees
Change from baseline to Weeks 4, 12, and 24 in active shoulder flexion range of motion
Time frame: Baseline and Weeks 4, 12, 24
Active shoulder flexion ROM (degrees) will be measured in the operated shoulder using a standard goniometer during clinical examination. Higher values indicate greater joint mobility. Unit : degrees
Change from baseline to Weeks 4, 12, and 24 in active shoulder extension range of motion
Time frame: Baseline and Weeks 4, 12, 24
Active shoulder extension ROM (degrees) will be measured in the operated shoulder using a standard goniometer during clinical examination. Higher values indicate greater joint mobility. Unit : degrees
Exploratory Outcome
Time frame: 4, 12 and 24 weeks
Change from baseline in functional score related to shoulder joints using Shoulder and Pain Disability Index (SPADI) questionnaire which is a self-administered questionnaire that assesses shoulder pain and functional disability. It consists of two domains: a pain domain with five questions assessing the severity of pain (0 = no pain to 10 = worst pain imaginable), and a disability domain with eight questions evaluating the degree of difficulty in performing activities of daily living requiring upper-extremity use (0 = no difficulty to 10 = so difficult it requires help). The final score is calculated by summing the 5 pain items and 8 disability items, converting each subscale to a percentage of its maximum possible score, and averaging the two subscales to obtain a total score ranging from 0 to 100. higher scores indicating greater pain and disability (worse outcome).
Exploratory Outcome
Time frame: 4, 12 and 24 weeks
Change from baseline in functional score related to knee joints using The Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire which is a patient-reported questionnaire used to assess pain, stiffness, and physical function in individuals with knee osteoarthritis. The questionnaire consists of 24 items divided into three subscales: pain (5 items), stiffness (2 items), and physical function (17 items). Each item is scored on a scale from 0 to 4, and the total score ranges from 0 to 96, with higher scores indicating worse pain, stiffness, and functional limitation.
Exploratory Outcome
Time frame: 4, 12 and 24 weeks
Pain score will be assessed based on the change from baseline in the Numeric Rating Scale (NRS) from 1-10 where 0 indicates no pain and 10 indicates the worst pain imaginable.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Arthroscopic Surgery
Recruiting
Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block for Analgesia in Arthroscopic Shoulder Surgery
Postoperative Pain, Acute, Shoulder Pain
Active, not recruitingPhase 2
Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder
Orthopedics, Traumatology
Recruiting
Blood Flow Restriction Training in Knee Arthropathy
Knee Arthroscopic Surgery, Arthrogenic Muscle Inhibition
Recruiting
Driving After Shoulder Surgery
Shoulder
RecruitingObservational study
SPSIP Block in Shoulder Artroscopy
Shoulder Arthroscopic Surgeries
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Prof. Dr. dr. Andri Marulitua Lubis Sp.OT(K) principal investigator
Siloam Hospitals Mampang
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing CG Synovia (Hyaluronic Acid 0.5%) in people with Arthroscopic Surgery, run by Daewoong Group Indonesia at 2 sites in Indonesia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety Evaluation (time frame: 4, 12 and 24 weeks). The study lists 26 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.